顺铂诱导survivin表达改变与宫颈癌细胞化疗敏感性的关系  

The role of survivin in the apoptosis of cervical cancer cell line induced by cisplatin

作　　者：赵晓利[1] 李力[1] 郭建新[1] 徐德斌[1] 胡珊[1] 陈竹钦[1] 

机构地区：[1]第三军医大学大坪医院野战外科研究所妇产科,重庆400042

出　　处：《第三军医大学学报》2005年第10期1023-1025,共3页Journal of Third Military Medical University

摘　　要：目的　探讨survivin基因在顺铂(DDP)诱导的宫颈癌细胞凋亡中的作用。方法　用宫颈癌Hela细胞株进行培养传代,MTT试验检测DDP不同药物浓度对宫颈癌细胞生长的抑制作用。分别在加药前、加药后2 4、48、72h和96h采用逆转录聚合酶链反应(RT PCR)和免疫印迹技术(Westernblot)检测survivinmRNA和蛋白的表达。同时利用流式细胞术定量检测细胞周期和细胞凋亡。结果　DDP对宫颈癌细胞生长均有明显的抑制作用,并有浓度和时间的依赖性。随浓度增加,宫颈癌细胞凋亡率表现先上升,后下降;随时间延长,在高浓度DDP组凋亡率明显增加,在低浓度DDP组凋亡率增加不明显。0 1mg/L和1mg/LDDP处理宫颈癌细胞,survivinmRNA和蛋白表达随作用时间的延长而增加。结论　小剂量顺铂处理宫颈癌细胞,survivinmRNA和蛋白表达随作用时间的延长而增加,这可能是宫颈癌细胞对化疗药物产生耐药性的重要因素之一。Objective To study the role of survivin in the apoptosis of cervical cancer cell line induced by cisplatin (DDP). Methods The inhibition effects of different doses of DDP on Hela cell line were assayed with MTT test. Cultured Hela cells were divided into 2 groups: DDP and control. DDP group was divided into 10, 4, 2, 1, 0.1, 0.01 mg/L groups. The expression of survivin was determined by RT-PCR and Western blotting on 24, 48, 72 and 96 h after Hela cells exposed to cisplatin. Apoptosis and cell cycle changes were determined by flow cytometry. Results DDP obviously inhibited the cervical cancer cell growth in a manner of dose- and time-dependent. Apoptosis induced by chemotherapeutical drug increased at first and then decreased as the concentrations of DDP got higher while as the time went by, the apoptosis in the high DDP concentration group increased significantly but in the low DDP concentration group increased slowly. As time went on, survivin mRNA and protein level were increased after Hela cells exposed to 0.1 mg/L and 1 mg/L of DDP. Conclusion A high expression of survivin was induced in Hela cells by low concentration of cisplatin in a time-dependent manner, which may be caused by chemoresistence of cervical carcinoma cells induced by chemotherapy agent.

关 键 词：SURVIVIN 凋亡 宫颈肿瘤 顺铂 

分 类 号：R737.33[医药卫生—肿瘤] R979.19[医药卫生—临床医学]